A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma
A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma
Recruiting · NCT05302284 · Registry updated 2023-12-18Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma | Neoplasms by Histologic Type, carcinoma, epithelial neoplasm, neoplasm, transitional cell carcinoma, urothelial carcinoma | Recruiting | Phase 3 | 2023-12-18 | NCT05302284 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| RemeGen Co., Ltd. | 36 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beijing Cancer Hospital | Beijing | China | 85 |
| Cancer Hospital Chinese Academy of Medical Sciences | Beijing | China | 29 |